Symptom burden (PRO-CTCAE) by time since last checkpoint inhibitor dose
| Frequency | % reporting | |||||||
| Overall (n=90) | <24 months (n=37) | 24 to <36 months (n=27) | 36+months (n=26) | P value | ||||
| Frequently/ almost constantly | Occasionally | Frequently/almost constantly | Occasionally | Frequently/almost constantly | Occasionally | Frequently/almost Constantly | ||
| Aching muscles | 12 | 22 | 3 | 22 | 22 | 12 | 15 | 0.11 |
| Aching joints | 17 | 24 | 14 | 22 | 19 | 12 | 19 | 0.74 |
| Headache | 6 | 11 | 8 | 19 | 7 | 19 | 0 | 0.56 |
| Vision problems* | 3 | 3 | 0 | 30 | 0 | 4 | 12 | <0.01 |
| Fever† | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -- |
| Severity | Severe/very severe | Moderate | Severe/ very severe | Moderate | Severe/ very severe | Moderate | Severe/ very severe | |
| Aching muscles | 10 | 28 | 0 | 20 | 15 | 29 | 14 | 0.50 |
| Aching joints | 4 | 37 | 0 | 26 | 0 | 33 | 13 | 0.35 |
| Headache | 7 | 41 | 6 | 29 | 7 | 33 | 8 | 0.98 |
| Itchy skin‡ | 9 | 16 | 14 | 22 | 7 | 4 | 4 | 0.18 |
| Numbness/tingling§ | 11 | 0 | 5 | 4 | 19 | 4 | 12 | 0.23 |
| Interference with daily activities | Quite a bit/Very much | Somewhat | Quite a bit/very much | Somewhat | Quite a bit/very much | Somewhat | Quite a bit/very much | |
| Aching muscles | 6 | 11 | 0 | 20 | 5 | 14 | 14 | 0.54 |
| Aching joints | 9 | 16 | 5 | 26 | 0 | 7 | 27 | 0.10 |
| Headache | 2 | 12 | 0 | 14 | 7 | 8 | 0 | 0.89 |
| Numbness/tingling | 9 | 0 | 0 | 27 | 18 | 11 | 11 | 0.05 |
*Only frequency is available for vision problems in the PRO-CTCAE.
†Only frequency is available for fever in the PRO-CTCAE.
‡Only severity of itchy skin is included in the PRO-CTCAE.
§Only severity and interference of numbness/tingling is included in the PRO-CTCAE.
PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Event.